HC Wainwright & Co. Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Immix Biopharma with a Buy rating and a price target of $7.
July 01, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Immix Biopharma with a Buy rating and a price target of $7.
The initiation of coverage with a Buy rating and a price target of $7 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Immix Biopharma in the short term. Such ratings often lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100